Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: association with hyperglycaemia, insulin-resistance, adiponectin and plasminogen activator inhibitor-1.
OBJECTIVE
The metabolic syndrome (MS) is associated with an increased cardiovascular risk. Patients with the MS have endothelial dysfunction, decreased circulating adiponectin, and a high expression of angiogenic inhibitors such as plasminogen activator inhibitor-1 (PAI-1). We hypothesized that such patients, in the event of a coronary occlusion, might exhibit a less developed collateral circulation.


RESULTS
Three hundred and eighty-seven consecutive patients with at least one coronary occlusion of a major coronary vessel at diagnostic angiography were prospectively enrolled. Collateral development was graded with validated angiographic methods. The MS was defined according to the ATP-III definition. Fasting glucose, adiponectin, insulin concentrations, and PAI-1 were measured at the time of angiography. MS was associated with less developed collateral vessels (P = 0.005). In multivariable analysis adjusting for potential confounding factors including the duration of coronary occlusion (P = 0.0001), fasting glycaemia (P = 0.0007), low adiponectin concentration (P = 0.01), insulin-resistance (HOMA-IR; P = 0.01), high circulating PAI-1 concentration (P = 0.01), and hypertension (P = 0.008) were independently associated with poor coronary collateral vessel development.


CONCLUSIONS
This study shows that in patients with coronary occlusion, collateral circulation is impaired in patients with the MS. This association is partly related to fasting glycaemia and to key parameters linked to insulin resistance.
Mouquet
Frédéric
F
Departments of Cardiology, Centre Hospitalier Régional Universitaire, Lille, France.
Cuilleret
François
F
Susen
Sophie
S
Sautière
Karine
K
Marboeuf
Philippe
P
Ennezat
Pierre Vladimir
PV
McFadden
Eugène
E
Pigny
Pascal
P
Richard
Florence
F
Hennache
Bernadette
B
Vantyghem
Marie Christine
MC
Bertrand
Michel
M
Dallongeville
Jean
J
Jude
Brigitte
B
Van Belle
Eric
E
D052242:Adiponectin / Q000378:metabolism; D000368:Aged; D003097:Collateral Circulation / Q000502:physiology*; D017023:Coronary Angiography; D054059:Coronary Occlusion / Q000150:complications* / Q000378:metabolism; D003925:Diabetic Angiopathies / Q000150:complications* / Q000378:metabolism; D005260:Female; D006801:Humans; D006943:Hyperglycemia / Q000209:etiology / Q000503:physiopathology; D007333:Insulin Resistance / Q000502:physiology; D008297:Male; D024821:Metabolic Syndrome / Q000209:etiology* / Q000378:metabolism / Q000503:physiopathology; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism; D011446:Prospective Studies; D013234:Stem Cells / Q000378:metabolism
D052242:Adiponectin; D017395:Plasminogen Activator Inhibitor 1